Crohn’s Disease - Pharmacy Freak

Mechanism of Action of Vedolizumab (Entyvio)

April 10, 2026July 11, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Vedolizumab is a humanized IgG1 monoclonal antibody used for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. It selectively targets the gastrointestinal immune system, offering gut-specific immunomodulation with minimal systemic immunosuppression. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Bioavailability Not applicable (IV administration) Half-life ~25.5 days Volume … Read more

Mechanism of Action of Infliximab (Remicade)

April 10, 2026July 6, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Infliximab is a chimeric (murine-human) IgG1 monoclonal antibody that targets tumor necrosis factor‑α (TNF‑α). It is used to treat a range of autoimmune and inflammatory disorders, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and plaque psoriasis. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion … Read more

Mechanism of Action of Natalizumab (Tysabri)

April 10, 2026July 5, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Natalizumab is a humanized IgG4 monoclonal antibody targeting the α4 integrin subunit. It’s approved for relapsing-remitting multiple sclerosis (RRMS) and moderate to severe Crohn’s disease. By blocking leukocyte adhesion, it prevents immune cell migration into the brain and gut. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Half-life ~11 days Distribution … Read more

Mechanism of Action of Adalimumab (Humira)

April 10, 2026July 4, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Adalimumab is a fully human monoclonal IgG1 antibody that specifically targets tumor necrosis factor‑α (TNF‑α). By neutralizing TNF‑α, it reduces inflammation across a variety of autoimmune conditions, including rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease, ulcerative colitis, and plaque psoriasis. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Subcutaneous … Read more

Mechanism of Action of Entyvio (Vedolizumab)

April 10, 2026July 4, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Entyvio (vedolizumab) is a recombinant humanized IgG1 monoclonal antibody that targets the α4β7 integrin on gut-homing T-lymphocytes. It is approved for moderate to severe ulcerative colitis and Crohn’s disease, particularly in patients who have not responded to or cannot tolerate TNF antagonists. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion (300 mg) … Read more

Mechanism of Action of Stelara (Ustekinumab)

April 10, 2026July 2, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Stelara (ustekinumab) is a fully human IgG1κ monoclonal antibody designed to target key cytokines involved in immune-mediated diseases. It selectively binds to the p40 subunit common to interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their interaction with cell surface receptors. Stelara is approved for several chronic inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn’s disease, … Read more